Symrise AG (OTCMKTS:SYIEY – Get Rating) – Research analysts at Jefferies Financial Group reduced their FY2023 EPS estimates for shares of Symrise in a report issued on Sunday, January 22nd. Jefferies Financial Group analyst C. Counihan now forecasts that the company will post earnings of $0.94 per share for the year, down from their previous estimate of $0.99. The consensus estimate for Symrise's current full-year earnings is $0.89 per share. Jefferies Financial Group also issued estimates for Symrise's FY2024 earnings at $1.13 EPS.
Get Symrise alerts:Other equities research analysts have also issued research reports about the stock. JPMorgan Chase & Co. upped their target price on shares of Symrise from €107.00 ($116.30) to €110.00 ($119.57) in a report on Monday, December 5th. Berenberg Bank raised shares of Symrise from a "hold" rating to a "buy" rating in a research report on Thursday, January 19th. Finally, The Goldman Sachs Group cut shares of Symrise from a "buy" rating to a "neutral" rating in a research report on Sunday, November 27th.
Symrise Stock Performance
Symrise stock opened at $26.83 on Wednesday. Symrise has a 52-week low of $22.20 and a 52-week high of $31.37. The company has a fifty day simple moving average of $27.86 and a 200-day simple moving average of $26.80. The company has a quick ratio of 1.53, a current ratio of 2.59 and a debt-to-equity ratio of 0.65.About Symrise
(Get Rating)
Symrise AG is a global supplier of fragrances, flavorings, cosmetic active ingredients and raw materials, as well as functional ingredients. It operates through the following three segments: Scent & Care, Flavor and Nutrition. The Scent and Care segment develops, produces and sells fragrances, cosmetic ingredients, aroma molecules and mint aromas.
Featured Articles
- Get a free copy of the StockNews.com research report on Symrise (SYIEY)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Receive News & Ratings for Symrise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Symrise and related companies with MarketBeat.com's FREE daily email newsletter.